<!doctype html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
  <meta name="description" content="Interventional Eligibility">
  <meta name="author" content="AlcHepNet">
  <link rel="icon" href="../favicon.ico">
  <title>AlcHepNet - Interventional Study Eligibility and Enrollment</title>
  <link href="../bootstrap.min.css" rel="stylesheet">
  <link href="../main.css" rel="stylesheet">
  <link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.4/css/all.min.css" rel="stylesheet">
  <script src="https://code.jquery.com/jquery-3.6.0.min.js"></script>
</head>

<body>
  <div id="navbar-include"></div>
  <div id="search-modal-include"></div>

  <main role="main">
    <div class="container marketing">
      <div class="container">
        <h3 class="section-title">AlcHepNet Clinical Trial Eligibility and Enrollment</h3>
        <p class="lead"><strong>Please note that recruitment is closed.</strong></p>
        <div class="row featurette">
          <div class="col lead">

            Inclusion Criteria
            <ol style="margin-top:1ex; margin-bottom:1ex;">
              <li style="margin-top:0.7ex;">AH, as defined by the NIAAA pan-consortia for AH:</li>
              <ol style="margin-top:1ex; margin-bottom:1ex;" type="a">
                <li style="margin-top:0.7ex;">Onset of jaundice <b>(defined as serum total bilirubin >3 mg/dL)</b>
                  within the prior 8 weeks to
                  screening visit</li>
                <li style="margin-top:0.7ex;">Regular consumption of alcohol with an intake of > 40 gm daily or >280gm
                  weekly
                  on average for women and > 60 gm daily or >420gm weekly on average for men
                  for 6 months or more, with less than 8 weeks of abstinence before onset of jaundice</li>
                <li style="margin-top:0.7ex;">AST > 50 IU/l</li>
                <li style="margin-top:0.7ex;">AST:ALT > 1.5 and both values < 400 IU/l</li>
                <li style="margin-top:0.7ex;">and/or histological evidence of AH*</li>
                <p>* In patients with possible AH or AH with confounding factors such as possible ischemic
                  hepatitis, possible DILI, uncertain history of alcohol use (e.g., patient denies excessive alcohol
                  use), and atypical/abnormal laboratory tests (e.g., AST < 50 IU/mL or> 400 IU/mL,
                    AST/ALT ratio < 1.5), antinuclear antibody> 1:160 or SMA > 1:80, a liver biopsy will be
                      performed to confirm AH and exclude competing etiologies</p>
              </ol>
              <li style="margin-top:0.7ex;">MELD 20-35 on day of randomization.
              </li>
              <li style="margin-top:0.7ex;">Age &ge; 21</li>
            </ol>
            Exclusion Criteria
            <ol style="margin-top:1ex; margin-bottom:1ex;">
              <li style="margin-top:0.7ex;">MELD SCORE <20 or> 35</li>
              <li style="margin-top:0.7ex;">Active sepsis (positive blood or ascitic cultures) with Systemic
                Inflammatory Response
                Syndrome (SIRS) or hemodynamic compromise requiring intravenous pressors to
                maintain tissue perfusion</li>
              <li style="margin-top:0.7ex;">Pneumonia as evidenced by radiological exam</li>
              <li style="margin-top:0.7ex;">Multi-organ failure</li>
              <li style="margin-top:0.7ex;">Renal failure defined by GFR < 35 mL/min.</li>
              <li style="margin-top:0.7ex;">Clinically active C. diff infection</li>
              <li style="margin-top:0.7ex;">History of imaging of the liver (ultrasound, computerized tomography or
                magnetic
                resonance) showing other causes of jaundice</li>
              <li style="margin-top:0.7ex;">History of other liver diseases including hepatitis B (positive HBsAg or HBV
                DNA),
                hepatitis C (positive HCV RNA), autoimmune hepatitis, Wilson disease, genetic
                \hemochromatosis, alpha1-antitrypsin deficiency or strong suspicion of Drug Induced
                Liver Injury (DILI). Previously treated hepatitis C that was cured (sustained virological response
                with negative RNA &ge;24 weeks following treatment) is not an exclusion.</li>
              <li style="margin-top:0.7ex;">History of HIV infection (positive HIV RNA or on treatment for HIV
                infection)</li>
              <li style="margin-top:0.7ex;">History or presence of cancer (including hepatocellular carcinoma) other
                than non-melanoma
                skin cancer</li>
              <li style="margin-top:0.7ex;">History of other significant medical problems such as autoimmune diseases,
                severe
                asthma, psoriasis, Inflammatory Bowel Disease (IBD), etc. that might require
                immunosuppressive treatments</li>
              <li style="margin-top:0.7ex;">Pregnancy or breastfeeding</li>
              <li style="margin-top:0.7ex;">Prior exposure to experimental therapies in last 3 months</li>
              <li style="margin-top:0.7ex;">Prior exposure to systemic corticosteroid (glucocorticoid) or
                immunosuppressive therapy
                for more than 4 days within previous 30 days</li>
              <li style="margin-top:0.7ex;">Need for inotropic pressor support to maintain perfusion to critical organs
                within prior
                48 hours before randomization and initiation of experimental treatment</li>
              <li style="margin-top:0.7ex;">Clinically significant pancreatitis- abdominal pain, elevated lipase (> 3 X
                ULN) and at least
                edema of pancreas with fat-stranding on CT scan</li>
              <li style="margin-top:0.7ex;">Total WBC count > 30,000/mm3</li>
              <li style="margin-top:0.7ex;">Known allergy or intolerance to therapeutic agents to be tested</li>
              <li style="margin-top:0.7ex;">Inability to voluntarily obtain informed consent from participant or
                guardian</li>
              <li style="margin-top:0.7ex;">Perceived inability to follow study procedures and comply with protocol</li>
              <li style="margin-top:0.7ex;">Platelet count < 40,000 k/cumm.</li>
              <li style="margin-top:0.7ex;">Positive PCR test for COVID-19 within 7 days prior to baseline day 0 visit*
              </li>
              <p>*Positive PCR test for COVID-19 is exclusionary only during the screening period. If a patient tests
                positive any time after baseline randomization, a positive PCR test for COVID-19 will be considered as a
                SAE.</p>
              <li style="margin-top:0.7ex;">Active gastrointestinal bleeding defined as hematemesis or melena with a
                decrease
                in hemoglobin more than 2 g/dl in 24 hrs. Due to gastrointestinal bleeding, or with a decrease in mean
                arterial BP to < 65 mmHg</li>
            </ol>
            <p>
              The participants for this study will be recruited from a hospitalized population of participants
              meeting the eligibility criteria outlined above who live within one day travel from one of the
              participating clinical centers and who have provided informed consent to participate in this
              clinical trial and who are willing to continue their participation for the anticipated follow-up
              period of the trial. Although the primary endpoint is survival at 90 days, follow-up visits will be
              continued up to 6 months.
            </p>

          </div>
        </div>
        <!-- <hr class="featurette-divider">
        <div class="row featurette">
          <div class="col">
          <h2 class="featurette-heading">AlcHepNet Organizations</h2>
            <img class="org-logo img-fluid mx-auto" src="sites_20250610.png" alt="Participating organization logos"/>
          </div>
        </div>

        <hr class="featurette-divider">

        <div class="row featurette">
        <div class="col text-center">
			<p class="lead">AlcHepNet is a clinical and translational research initiative funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of NIH.</p>
         </div>
        </div> -->
        <!-- /END THE FEATURETTES -->
        <!-- <hr class="featurette-divider"> -->
      </div><!-- /.container -->


    </div>
  </main>

  <div id="footer-include"></div>

  <script src="../popper.min.js"></script>
  <script src="../bootstrap.min.js"></script>
  <script src="../simple-dropdown.js"></script>
  <script>
    $(function () {
      $("#navbar-include").load("../navbar.html", function () {
        $("#navbar-include a").each(function() {
          var href = $(this).attr("href");
          if (href && !href.startsWith("http") && !href.startsWith("#")) {
            $(this).attr("href", "../" + href);
          }
        });
        
        $("#navbar-include img").each(function() {
          var src = $(this).attr("src");
          if (src && !src.startsWith("http") && !src.startsWith("data:") && !src.startsWith("/")) {
            $(this).attr("src", "../" + src);
          }
        });
        console.log('Navbar loaded and links updated');
      });
      $("#search-modal-include").load("../search-modal.html");
      $("#footer-include").load("../footer.html", function () {
        console.log('Footer loaded');
      });
    });
  </script>
</body>

</html>